Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

L0551000

Levonorgestrel

European Pharmacopoeia (EP) Reference Standard

Synonyma:

D(−)-Norgestrel, 13β-Ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one, 17α-Ethynyl-18-homo-19-nor-testosterone, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-yn-3-one, 18,19-Dinor-4-pregnen-20-yn-3-one, Levonorgestrel

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C21H28O2
Číslo CAS:
797-63-7
Molekulová hmotnost:
312.45
MDL number:
MFCD00199013
UNSPSC Code:
41116107
PubChem Substance ID:
329817365
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levonorgestrel

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

WWYNJERNGUHSAO-XUDSTZEESA-N

Gene Information

human ... PGR(5241)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levonorgestrel EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 10

1 of 10

Dienogest European Pharmacopoeia (EP) Reference Standard

Y0001785

Dienogest

Drospirenone ≥98% (HPLC)

Sigma-Aldrich

SML0147

Drospirenone

Desogestrel Related Compound C United States Pharmacopeia (USP) Reference Standard

USP

1173268

Desogestrel Related Compound C

Desogestrel impurity D British Pharmacopoeia (BP) Reference Standard

BP816

Desogestrel impurity D

D(−)-Norgestrel analytical standard

Supelco

N2260

D(−)-Norgestrel

Norethisterone European Pharmacopoeia (EP) Reference Standard

N1200000

Norethisterone

Ethinylestradiol British Pharmacopoeia (BP) Assay Standard

BP421

Ethinylestradiol

Etonogestrel ≥98% (HPLC)

Sigma-Aldrich

SML0356

Etonogestrel

Ethinyl Estradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1480

Ethinyl Estradiol

17α-Ethynylestradiol ≥98%

Sigma-Aldrich

E4876

17α-Ethynylestradiol

Ioannis D Gallos et al.
Obstetrics and gynecology, 121(6), 1165-1171 (2013-07-03)
To identify predictors and to estimate their prognostic accuracy for regression and relapse of endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system or oral progestogens. This was a cohort study of women treated with levonorgestrel-releasing intrauterine system or oral progestogens for
Jantien Visser et al.
The Cochrane database of systematic reviews, 3(3), CD003990-CD003990 (2013-04-02)
Adequate contraceptive advice is important in both women with diabetes mellitus type 1 and type 2 to reduce the risk of maternal and infant morbidity and mortality in unplanned pregnancies. A wide variety of contraceptives are available for these women.
Anita Nelson et al.
Obstetrics and gynecology, 122(6), 1205-1213 (2013-11-19)
To evaluate the efficacy and safety of two low-dose levonorgestrel intrauterine contraceptive systems. Nulliparous and parous women aged 18-35 years with regular menstrual cycles (21-35 days) requesting contraception were randomized to 3 years of treatment with one of two levonorgestrel
Abbey B Berenson et al.
Obstetrics and gynecology, 121(5), 951-958 (2013-05-03)
Many U.S. health care providers remain reluctant to prescribe intrauterine devices (IUDs) to teenagers as a result of concerns about serious complications. This study examined whether 15-19-year-old IUD users were more likely to experience complications, failure, or early discontinuation than
Andrew M Kaunitz et al.
Drugs, 72(2), 193-215 (2012-01-25)
Heavy menstrual bleeding (HMB) is a common problem in women of reproductive age and can cause irritation, inconvenience, self-consciousness and fear of social embarrassment. Our objective was to review and appraise literature identified from the MEDLINE and EMBASE databases to
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.